Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Search
3 "Chronic disease"
Article category
Publication year
Funded articles
Sulwon Lecture 2022
Opening the Precision Diabetes Care through Digital Healthcare
Joonyub Lee, Jin Yu, Kun-Ho Yoon
Diabetes Metab J. 2023;47(3):307-314.   Published online March 29, 2023
  • 5,906 View
  • 251 Download
AbstractAbstract PDFPubReader   ePub   
The national healthcare systems of every country in the world cannot sustain the rise in healthcare expenditure caused by chronic diseases and their complications. To sustain the national healthcare system, a novel system should be developed to improve the quality of care and minimize healthcare costs. For 20 years, our team developed patient-communicating digital healthcare platforms and proved their efficacy. National scale randomized control trials are underway to systematically measure the efficacy and economic benefits of this digital health care system. Precision medicine aims to maximize effectiveness of disease management by considering individual variability. Digital health technologies enable precision medicine at a reasonable cost that was not available before. The government launched the “National Integrated Bio-big Data Project” which will collect diverse health data from the participants. Individuals will share their health information to physicians or researchers at their will by gateway named “My-Healthway.’ Taken together, now we stand in front of the evolution of medical care, so-called “Precision medicine.” led by various kinds of technologies and a huge amount of health information exchange. We should lead these new trends as pioneers, not as followers, to establish and implement the best care for our patients that can help them to withstand their devastating diseases.
Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Päivi Maria Paldánius
Diabetes Metab J. 2020;44(6):785-801.   Published online September 15, 2020
  • 7,181 View
  • 288 Download
AbstractAbstract PDFPubReader   ePub   
Type 2 diabetes mellitus (T2DM) is a complex and progressive chronic disease characterised by elevating hyperglycaemia and associated need to gradually intensify therapy in order to achieve and maintain glycaemic control. Treating hyperglycaemia with sequential therapy is proposed to allow holistic assessment of the efficacy and risk-to-benefit ratio of each added component. However, there is an array of evidence supporting the scientific rationale for using synergistic, earlier, modern drug combinations to achieve glycaemic goals, delay the deterioration of glycaemic control, and, therefore, potentially preserve or slow down the declining β-cell function. Additionally, implementation of early combination(s) may lead to opportunities to combat clinical inertia and other hurdles to optimised disease management outcomes. This review aims to discuss the latest empirical evidence for long-term clinical benefits of this novel strategy of early combination in people with newly diagnosed T2DM versus the current widely-implemented treatment paradigm, which focuses on control of hyperglycaemia using lifestyle interventions followed by sequentially intensified (mostly metformin-based) monotherapy. The recent reported Vildagliptin Efficacy in combination with metfoRmin For earlY treatment of T2DM (VERIFY) study results have provided significant new evidence confirming long-term glycaemic durability and tolerability of a specific early combination in the management of newly diagnosed, treatment-naïve patients worldwide. These results have also contributed to changes in clinical treatment guidelines and standards of care while clinical implementation and individualised treatment decisions based on VERIFY results might face barriers beyond the existing scientific evidence.
Basic Research
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases
Siqi Hu, Eun-Hee Cho, Ji-Young Lee
Diabetes Metab J. 2020;44(2):234-244.   Published online March 24, 2020
  • 6,506 View
  • 161 Download
  • 20 Web of Science
  • 21 Crossref
AbstractAbstract PDFPubReader   

As a member of the class IIa histone deacetylases (HDACs), HDAC9 catalyzes the deacetylation of histones and transcription factors, commonly leading to the suppression of gene transcription. The activity of HDAC9 is regulated transcriptionally and post-translationally. HDAC9 is known to play an essential role in regulating myocyte and adipocyte differentiation and cardiac muscle development. Also, recent studies have suggested that HDAC9 is involved in the pathogenesis of chronic diseases, including cardiovascular diseases, osteoporosis, autoimmune disease, cancer, obesity, insulin resistance, and liver fibrosis. HDAC9 modulates the expression of genes related to the pathogenesis of chronic diseases by altering chromatin structure in their promotor region or reducing the transcriptional activity of their respective transcription factors. This review summarizes the current knowledge of the regulation of HDAC9 expression and activity. Also, the roles of HDAC9 in the pathogenesis of chronic diseases are discussed, along with potential underlying mechanisms.


Citations to this article as recorded by  
  • Impact of housing temperature on adipose tissue HDAC9 expression and adipogenic differentiation in high fat‐fed mice
    Samah Ahmadieh, Brandee Goo, Abdalrahman Zarzour, David Kim, Hong Shi, Praneet Veerapaneni, Ronnie Chouhaita, Nicole K. H. Yiew, Carla Dominguez Gonzalez, Akash Chakravartty, James Pennoyer, Nazeera Hassan, Tyler W. Benson, Mourad Ogbi, David J. Fulton, R
    Obesity.2024; 32(1): 107.     CrossRef
  • HDAC9 inhibition reduces skeletal muscle atrophy and enhances regeneration in mice with cigarette smoke-induced COPD
    Guixian Zheng, Chao Li, Xiaoli Chen, Zhaohui Deng, Ting Xie, Zengyu Huo, Xinyan Wei, Yanbing Huang, Xia Zeng, Yu Luo, Jing Bai
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(3): 167023.     CrossRef
  • Identification of HDAC9 and ARRDC4 as potential biomarkers and targets for treatment of type 2 diabetes
    Jing Liu, Lingzhen Meng, Zhihong Liu, Ming Lu, Ruiying Wang
    Scientific Reports.2024;[Epub]     CrossRef
  • HDAC9 as a Privileged Target: Reviewing its Role in Different Diseases and Structure-activity Relationships (SARs) of its Inhibitors
    Totan Das, Samima Khatun, Tarun Jha, Shovanlal Gayen
    Mini-Reviews in Medicinal Chemistry.2024; 24(7): 767.     CrossRef
  • Targeting histone deacetylases for cancer therapy: Trends and challenges
    Tao Liang, Fengli Wang, Reham M. Elhassan, Yongmei Cheng, Xiaolei Tang, Wengang Chen, Hao Fang, Xuben Hou
    Acta Pharmaceutica Sinica B.2023; 13(6): 2425.     CrossRef
  • Therapeutic approach of natural products that treat osteoporosis by targeting epigenetic modulation
    Guokai Zhang, Zhenying Liu, Zihan Li, Bing Zhang, Pengyu Yao, Yun Qiao
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Research Progress on Histone Deacetylase Inhibitors
    玉姜 汤
    Hans Journal of Medicinal Chemistry.2023; 11(02): 116.     CrossRef
  • HDAC9 Inhibition as a Novel Treatment for Stroke
    Hugh S. Markus
    Stroke.2023; 54(12): 3182.     CrossRef
  • Histone deacetylase 9 exacerbates podocyte injury in hyperhomocysteinemia through epigenetic repression of Klotho
    Min Liu, Yang Zhang, Ping Zhan, Wenjuan Sun, Chuanqiao Dong, Xiaohan Liu, Yujie Yang, Xiaojie Wang, Yusheng Xie, Chengjiang Gao, Huili Hu, Benkang Shi, Ziying Wang, Chun Guo, Fan Yi
    Pharmacological Research.2023; 198: 107009.     CrossRef
  • Molecular mechanism and therapeutic potential of HDAC9 in intervertebral disc degeneration
    Ming Lei, Hui Lin, Deyao Shi, Pan Hong, Hui Song, Bomansaan Herman, Zhiwei Liao, Cao Yang
    Cellular & Molecular Biology Letters.2023;[Epub]     CrossRef
  • Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
    Sylvia Fong, Bridget Yates, Choong-Ryoul Sihn, Aras N. Mattis, Nina Mitchell, Su Liu, Chris B. Russell, Benjamin Kim, Adebayo Lawal, Savita Rangarajan, Will Lester, Stuart Bunting, Glenn F. Pierce, K. John Pasi, Wing Yen Wong
    Nature Medicine.2022; 28(4): 789.     CrossRef
  • Active RhoA Exerts an Inhibitory Effect on the Homeostasis and Angiogenic Capacity of Human Endothelial Cells
    Michael Hauke, Robert Eckenstaler, Anne Ripperger, Anna Ender, Heike Braun, Ralf A. Benndorf
    Journal of the American Heart Association.2022;[Epub]     CrossRef
  • HDAC9 Contributes to Serous Ovarian Cancer Progression through Regulating Epithelial–Mesenchymal Transition
    Long Xu, Jian Wang, Buhan Liu, Jiaying Fu, Yuanxin Zhao, Sihang Yu, Luyan Shen, Xiaoyu Yan, Jing Su
    Biomedicines.2022; 10(2): 374.     CrossRef
  • Common protein-coding variants influence the racing phenotype in galloping racehorse breeds
    Haige Han, Beatrice A. McGivney, Lucy Allen, Dongyi Bai, Leanne R. Corduff, Gantulga Davaakhuu, Jargalsaikhan Davaasambuu, Dulguun Dorjgotov, Thomas J. Hall, Andrew J. Hemmings, Amy R. Holtby, Tuyatsetseg Jambal, Badarch Jargalsaikhan, Uyasakh Jargalsaikh
    Communications Biology.2022;[Epub]     CrossRef
  • Proposed minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life
    Zahra Salehi, Masoud Arabfard, Omid Sadatpour, Mina Ohadi
    Neurological Sciences.2021; 42(3): 951.     CrossRef
  • Emerging roles of SIRT6 in human diseases and its modulators
    Gang Liu, Haiying Chen, Hua Liu, Wenbo Zhang, Jia Zhou
    Medicinal Research Reviews.2021; 41(2): 1089.     CrossRef
  • Quis Custodiet Ipsos Custodes (Who Controls the Controllers)? Two Decades of Studies on HDAC9
    Claudio Brancolini, Eros Di Giorgio, Luigi Formisano, Teresa Gagliano
    Life.2021; 11(2): 90.     CrossRef
  • circ_0003204 Regulates Cell Growth, Oxidative Stress, and Inflammation in ox-LDL-Induced Vascular Endothelial Cells via Regulating miR-942-5p/HDAC9 Axis
    Huan Wan, Ting You, Wei Luo
    Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
  • Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer
    Chun Yang, Stéphane Croteau, Pierre Hardy
    Cellular Oncology.2021; 44(5): 997.     CrossRef
  • Dual HDAC/BRD4 inhibitors against cancer
    Negar Omidkhah, Farzin Hadizadeh, Razieh Ghodsi
    Medicinal Chemistry Research.2021; 30(10): 1822.     CrossRef
  • miR‐211‐5p is down‐regulated and a prognostic marker in bladder cancer
    Weisheng Wang, Zhiming Liu, Xuegang Zhang, Junning Liu, Junqing Gui, Maorong Cui, Yong Li
    The Journal of Gene Medicine.2020;[Epub]     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal